Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Candidiasis Therapeutics Market from 2024 to 2025?

The market size for therapeutics in candidiasis has been experiencing steady growth over the recent years. It’s projected that the market will increase from a worth of $3.19 billion in 2024 to $3.3 billion in 2025, presenting a compound annual growth rate (CAGR) of 3.4%. The growth seen in the previous period can be credited to factors such as a rise in the occurrence of candidiasis, the application and obstruction of antibiotics, infections acquired from hospitals, changes in the patterns of fungal resistance, as well as awareness and educational initiatives.

What Is the Projected Market Size of the Candidiasis Therapeutics Market?

The market size for candidiasis therapeutics is projected to experience stable growth in the upcoming years, reaching $3.83 billion in 2029 with a CAGR of 3.8%. The expected increase during the projection period can be credited to precision medicine methods, worldwide antifungal stewardship programs, rising incidence of candida auris, and international movements against antifungal resistance. Key trends during the prediction period encompass developments in drug delivery technologies, telemedicine and remote patient monitoring, patient-focused care, combination therapies, and cooperative research endeavours.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

Who are the Major Competitors in the Candidiasis Therapeutics Market Outlook?

Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

What Is Fueling Growth in the Candidiasis Therapeutics Market?

The surge in fungal infections is predicted to fuel the expansion of the candidiasis therapeutics market. Fungal infections are diseases provoked by an assortment of fungi, which can impact the skin, mucous membranes, and the interior organs of humans. An increasing volume of individuals with weakened immune systems and those with fungal infections enhance the vulnerability to candidiasis. This necessitates manufacturers to craft and provide specialized and efficacious antifungal medications aimed at the underlying fungal pathogens. These drugs offer relief from symptoms, avert complications, bolster patient recovery, curtail the proliferation of Candida infections in healthcare facilities, and aid in improving patient outcomes. For example, the University of Minnesota, a research-based US university, claimed in January 2024 that fungal infections are responsible for more than 3.75 million fatalities yearly, with nearly 2.55 million of these deaths directly linked to fungal diseases. Consequently, the mounting prevalence of fungal infections will boost the advancement of the candidiasis therapeutics market. The growth of the candidiasis therapeutics market is likely to be powered by the escalation in the number of clinical trials. These trials are investigative studies intended to assess the safety and effectiveness of new medical treatments, interventions, pharmaceuticals, or devices on humans. Clinical trials are crucial in the progress of candidiasis therapeutics as they offer a systematic and rigorous method to gauge the safety and effectiveness of potential treatments. In May 2023, according to ClinicalTrials.gov, a component of the National Institutes of Health (NIH), a US governmental entity responsible for conducting and underpinning medical research, reported that about 437,533 clinical trials got registered in 2023. This figure indicates an increase from the 399,499 studies registered in 2022 throughout all 50 American states and across 221 countries. Hence, the rise in clinical trials contributes to the momentum of the candidiasis therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp

Which Candidiasis Therapeutics Market Segments Are Growing the Fastest?

The candidiasis therapeutics market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Other Treatments

2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis

3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations

4) By Patient Population: Adults, Pediatrics

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments

2) By Surgery: Surgical Debridement, Organ Removal

3) By Other Treatments: Probiotics, Home Remedies, Lifestyle Modifications

Which Industry Trends Are Shaping the Future of the Candidiasis Therapeutics Market?

The candidiasis therapeutics market is experiencing advancements with leading operators creating novel drugs like BREXAFEMME (ibrexafungerp tablets) to curb the prevalence of recurrent vulvovaginal candidiasis (RVVC) among mature women. The oral, non-azole based BREXAFEMME is a therapeutic option for vulvovaginal candidiasis (VVC), also characterized as chronic yeast infections, and it helps in minimizing the recurrence of RVVC. For instance, in December 2022, the U.S. pharmaceutical corporation, Scynexis Inc., gained approval from the US Food and Drug Administration (FDA) for the use of BREXAFEMME for the treatment and recurrence reduction of VVC and RVVC. This medication contributes by impeding the proliferation of Candida albicans, the fungus responsible for VVC. Additionally, BREXAFEMME is both safe and efficacious for the treatment of VVC, necessitating a prescription with a suggested dosage of a single 150-mg pill to be consumed orally once daily for a day.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Which Countries Are Leading the Candidiasis Therapeutics Market?

North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13182

This Report Delivers Insight On:

1. How big is the candidiasis therapeutics market, and how is it changing globally?

2. Who are the major companies in the candidiasis therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the candidiasis therapeutics market right now?

4. Which products or customer segments are growing the most in the candidiasis therapeutics market?

5. What factors are helping or slowing down the growth of the candidiasis therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model